[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334673-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334673-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","distinction-of-alk-fusion-gene-and-egfr-mutation-positive-lung-cancer-with-tumor-markers","Distinction of ALK fusion gene - and EGFR mutation-positive lung cancer with tumor markers","","Background: Predicting individual gene mutations from clinical background alone remains difficult. Tumor markers may support prediction of each gene mutation, enabling timely genetic testing and intervention. Methods: Using a clinical database, 134 advanced or recurrent ALK-positive cases and 172 advanced or recurrent EGFR-positive cases were analyzed with defined marker cutoffs and a CYFRA21-1:CEA ratio threshold. Results and conclusions summarize comparative positivity and ratio differences between groups.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/distinction-of-alk-fusion-gene-and-egfr-mutation-positive-lung-cancer-with-tumor-markers/334673/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/distinction-of-alk-fusion-gene-and-egfr-mutation-positive-lung-cancer-with-tumor-markers/334673.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is predicting gene mutations difficult based only on clinical background?","Question",{"text":63,"@type":64},"Clinical background alone is insufficient because features common to ALK-positive and EGFR-positive NSCLC overlap. This makes it hard to distinguish the underlying mutations for each patient.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which tumor markers and thresholds were used in the analysis?",{"text":68,"@type":64},"Carcinoembryonic antigen (CEA) and soluble fragment of cytokeratin 19 (CYFRA21-1) were evaluated using institutionally defined cutoffs. A positive CYFRA21-1:CEA ratio was defined as 0.7 or higher.",{"name":70,"@type":61,"acceptedAnswer":71},"How do tumor marker positivity and CYFRA21-1:CEA ratios differ between ALK-positive and EGFR-positive lung cancer?",{"text":72,"@type":64},"The CEA positivity rate was higher in EGFR-positive lung cancer, while CYFRA21-1 positivity and median CYFRA21-1:CEA ratios were higher in ALK-positive lung cancer. These findings support the markers’ role in distinguishing mutation types.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334673,1790197954,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":22,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","DOI: 10.1111/1759-7714.15268  \nORIGINA L ARTICLE  \nDistinction ofALK fusion gene-and EGFR mutation-positive lung cancer with tumor markers  \nTakahiro Akita 1,2 | Ryo Ariyasu 1  | Sho Kakuto 1 | Keiki Miyadera 1 | Ayu Kiritani 1 | Ryosuke Tsugitomi 1 | Yoshiaki Amino 1  | Ken Uchibori 1  | Satoru Kitazono 1 | Noriko Yanagitani 1 | Sadatomo Tasaka 2 | Makoto Nishio 1   \n1Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan 2Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan  \nCorrespondence  \nRyo Ariyasu, Department of Thoracic Medical Oncology, the Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan.  \nEmail: [ryo.ariyasu@jfcr.or.jp](ryo.ariyasu@jfcr.or.jp)  \nAbstract  \nBackground: It is difficult to predict gene mutations individually based on clinical background alone. Tumor markers may help to predict each gene mutation. Identifying tumor markers that can predict gene mutation will facilitate timely genetic testing and intervention.  \nMethods: We selected 134 cases of advanced or recurrent ALK-positive and 172 cases of advanced or recurrent EGFR-positive lung cancer from our clinical database. The cutoff values for the tumor markers were defined as 5.0 ng/mL or higher for carcinoembryonic antigen (CEA) and 3.5 ng/mL or higher for soluble fragment of cytokeratin 19 (CYFRA21-1) in accordance with the institutional standards. A positive CYFRA21-1:CEA ratio was defined as 0.7 or higher.  \nResults: The CEA-positivity rate was 49% for ALK-positive lung cancers and 73% for EGFR-positive lung cancers, which was significantly different (p \u003C 0.001) . The CYFRA21-1 positivity rate was significantly higher in ALK-positive lung cancer (36%) compared with EGFR-positive lung cancer (23%) (p = 0.034) . The median CYFRA21-1:CEA ratio was 0.395 for the ALK group, which was significantly higher compared with 0.098 for the EGFR group (p \u003C 0.001) . These trends were similar when excluding histology other than adenocarcinoma. The median time-to-treatment failure (TTF) for initial tyrosine kinase inhibitor (TKI) therapy was 308 days for the high CYFRA21-1:CEA ratio group and 617 days for the low CYFRA21-1:CEA ratio group for ALK-positive lung cancer (p = 0.100) .  \nConclusions: A higher proportion of patients with ALK-positive lung cancer were CYFRA21-1 positive and had higher CYFRA21-1:CEA ratios compared with EGFRpositive lung cancer patients.  \nKEYW ORD S  \nALK-positive lung cancer, CEA, CYFRA21-1, EGFR-positive lung cancer, tumor marker  \nINTRODUCTION  \nLung cancer remains the leading cause of cancer-related deaths and has poor prognosis; however, treatment outcomes of non-small cell lung cancer (NSCLC) have improved dramatically with the approval of molecular targeted drugs and the discovery of driver gene mutations. Targeting driver gene mutations with specific drugs has  \nbeen adopted as standard therapy, 1 and the prognosis of NSCLC patients has markedly improved over the last decade,2 highlighting the importance of driver gene mutations in patients with NSCLC. The most common driver gene mutations identified in NSCLC are EGFR mutations and the ALK fusion gene. EGFR mutations (EGFR positive) in NSCLC are frequent among Asian populations and account for 40%–50% of NSCLC cases and approximately  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd.  \n20% among Caucasian patients.3 NSCLC with an ALK fusion gene (ALK-positive) is the second most common type and accounts for 3%–5% of all cases.4,5  \nThe prognosis of patients with EGFR-and ALK-positive NSCLC has significantly improved following treatment with EGFR tyrosine kinase inh","cbCaigXz7WdqgOCk","https://ap.wps.com/l/cbCaigXz7WdqgOCk","pdf",1679272,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why is predicting gene mutations difficult based only on clinical background?\",\"answer\":\"Clinical background alone is insufficient because features common to ALK-positive and EGFR-positive NSCLC overlap. This makes it hard to distinguish the underlying mutations for each patient.\"},{\"question\":\"Which tumor markers and thresholds were used in the analysis?\",\"answer\":\"Carcinoembryonic antigen (CEA) and soluble fragment of cytokeratin 19 (CYFRA21-1) were evaluated using institutionally defined cutoffs. A positive CYFRA21-1:CEA ratio was defined as 0.7 or higher.\"},{\"question\":\"How do tumor marker positivity and CYFRA21-1:CEA ratios differ between ALK-positive and EGFR-positive lung cancer?\",\"answer\":\"The CEA positivity rate was higher in EGFR-positive lung cancer, while CYFRA21-1 positivity and median CYFRA21-1:CEA ratios were higher in ALK-positive lung cancer. These findings support the markers’ role in distinguishing mutation types.\"}]","Distinction of ALK fusion gene - and EGFR mutation-positive lung cancer with tumor markers | PDF",1790007789,23,[146],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/ac0fb69db4764d330e555961b05a2294.webp",983,1291]